Symptoms and Functional Burden
Cross-source consensus on Symptoms and Functional Burden from 1 sources and 4 claims.
1 sources · 4 claims
Uses
Risks & contraindications
Other
Highlighted claims
- Dyspnoea was recorded in 69.7% during baseline and 73.3% during the first 12 months of follow-up. — Post-progression treatment patterns in systemic autoimmune rheumatic disease-associated interstitial lung disease: insights from a US retrospective, observational study
- ILD-related respiratory symptoms were common before and after progression. — Post-progression treatment patterns in systemic autoimmune rheumatic disease-associated interstitial lung disease: insights from a US retrospective, observational study
- Fatigue increased after progression. — Post-progression treatment patterns in systemic autoimmune rheumatic disease-associated interstitial lung disease: insights from a US retrospective, observational study
- Oxygen supplementation was the most common non-pharmacological intervention and likely reflected high dyspnoea and impaired functional respiratory capacity. — Post-progression treatment patterns in systemic autoimmune rheumatic disease-associated interstitial lung disease: insights from a US retrospective, observational study